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Abstract
Background. The use of mycophenolate mofetil (MMF) in autoimmune disease is often limited by
adverse effects. In this single-centre, open label, parallel design study, we investigated whether
enteric-coated mycophenolate sodium (MS) is better tolerated and therefore more efficacious than
MMF in primary systemic vasculitis (PSV) and systemic lupus erythematosus (SLE).
Methods. Forty patients with vasculitis or systemic lupus erythematosus (SLE) due to commence
MMF for active disease or remission maintenance were randomized to receive either 1440 mg/day
MS or 2000 mg/day MMF (18 PSV, 2 SLE per group) in addition to corticosteroids. Random allocation
was performed by minimization for age, diagnosis and renal function using a computer algorithm.
Twenty-five were treated for active disease (5 first-line therapy, 20 salvage therapy) and 15 for re-
mission maintenance. The composite primary end point was treatment failure and/or drug intoler-
ance over 12 months. Treatment failure was defined as failure to achieve remission by 6 months or
disease relapse and treatment intolerance was defined as inability to tolerate and maintain the
target dose of MS or MMF within 12 months.
Results. Forty patients were included in the analyses. MS was associated with a lower primary end
point rate [hazard ratio (HR) 0.37; 95% CI 0.17–0.80; P = 0.012] (11/20, 55% patients) compared
with MMF (17/20, 85% patients). Treatment failure alone was less common in the MS group (HR
0.28; 95% CI 0.095–0.82; P = 0.020), although drug intolerance did not differ between groups (HR
0.53; 95% CI 0.20–1.42; P = 0.21). Despite randomization, patients in the MMF group may have had
a higher baseline risk for treatment failure; more MMF patients had refractory disease and granulo-
matosis with polyangiitis (Wegener’s). A glomerular filtration rate (GFR) ≤40 mL/min was asso-
ciated with intolerance. Serious adverse events were common (55% MMFand 45% MS patients).
Conclusions. No differences in treatment tolerance were observed between the MS and MMF
groups. Despite similar treatment intolerance, MS was associated with improved efficacy in PSV
and SLE compared with MMF. However, baseline group imbalances in factors potentially affecting
remission and relapse may have influenced the results. Treatment intolerance was common and
strongly associated with low GFR. Further treatment trials are warranted to investigate the effect of
GFR on mycophenolic acid pharmacokinetics and clinical outcomes (ISRCTN83027184; EUDRACT
2005-002207-16; Funding Novartis UK).
Keywords: enteric-coated mycophenolate sodium; mycophenolate mofetil; primary systemic vasculitis; randomized trial;
systemic lupus erythematosus
Background
Primary systemic vasculitis (PSV) and systemic lupus ery-
thematosus (SLE) are the two major subgroups of multi-
system autoimmune disease. Both conditions demon-
strate similar treatment responses and untreated are as-
sociated with poor outcomes. The standard therapy,
cyclophosphamide with high-dose corticosteroid [1–3], is
associated with primary treatment failures, relapses and
toxicity [4], particularly infections, malignancies and infer-
tility [5]. Improved therapies are required.
Mycophenolic acid (MPA) is an immunosuppressant that
reversibly inhibits inosine 5-monophosphate dehydrogen-
ase (IMPDH), a critical enzyme in de novo guanosine nu-
cleotide synthesis [6]. T- and B-lymphocyte proliferation is
dependent on the de novo pathway [7], unlike other cells
which utilize the salvage pathway for guanosine synthesis.
MPA is associated with lower rates of amenorrhoea and
malignancy compared with the alkylating agent, cyclo-
phosphamide which inhibits cell division [8, 9].
The MPA ester, mycophenolate mofetil (MMF) is an ef-
fective component of anti-rejection therapy in solid-organ
© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For permissions, please email: journals.permissions@oup.com.
Clin Kidney J (2014) 7: 562–568
doi: 10.1093/ckj/sfu096
Advance Access publication 16 September 2014
transplantation. Treatment with MMF is complicated by
dose-dependent gastrointestinal intolerance, which may
result in suboptimal dosing and loss of efficacy. MMFunder-
goes rapid gastric absorption and systemic de-esterifica-
tion to MPA, whereas another MPA preparation, enteric-
coated mycophenolate sodium (MS), developed as a strat-
egy to reduce gastrointestinal toxicity, allows delayed MPA
release in the small intestine [10]. In transplantation there
is no difference in efficacy between MMF and MS [11, 12].
Results of transplant cross-over studies suggest that gastro-
intestinal intolerance is less with MS compared with MMF
[13–18]; however, no difference in tolerance has been de-
monstrated in blinded randomized trials [19, 20].
MMF is a promising treatment for autoimmune disease.
Trials in lupus nephritis have found MMF to have similar ef-
ficacy to cyclophosphamide for remission induction [8,
21–24] and maintenance [25]. In one small ANCA-asso-
ciated vasculitis (AAV) trial remission occurred in 77.8% of
MMF patients compared with 47.1% of cyclophosphamide
patients [26]. Uncontrolled prospective series provide
further support for MMF use in PSV for both remission in-
duction [27, 28] and maintenance [29–31]. However, a
156 patient randomized trial found MMF to be less effect-
ive than azathioprine for remission maintenance in AAV
[32]. There is considerable ‘off label’ use of MMF as a
second line therapy for these disorders. Because MS may
reduce drug intolerance, it has the potential to be an ef-
fective therapy. We performed a randomized controlled
trial of MMF compared with MS in patients with SLE and
PSV to investigate differences in efficacy and tolerability.
Materials and methods
This is an open-label, two group, single centre randomized
trial was performed. Patients were recruited from the
Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, Cam-
bridge. All patients provided written informed consent.
The trial was designed by the investigators, received ethical
and regulatory approval and was conducted according to
the European Union Clinical Trials Directive 2001, and the
Declaration of Helsinki (EUDRACT 2005-002207-16, clinical
trials registration: ISRCTN 83027184). The trial was spon-
sored by Cambridge University Hospitals NHS Foundation
Trust and a research grant to fund trial conduct was pro-
vided by Novartis UK.
Patients were included if they had a diagnosis of vasculitis
[33] or SLE [34] according to American College of Rheuma-
tology criteria and were about to commence MPA as part of
their routine care or had been taking MMF 2000 mg/day or
less for at least 3 months with inadequate disease control.
Patients with active disease or those requiring remission
maintenance therapy were eligible. Patients were excluded
if they had active infection, hypersensitivity to MMF, a
history of cancer, elective surgery planned, had received an
investigational drug within 4 weeks of recruitment, any con-
dition that would cause the study to be detrimental to the
patient, or were breastfeeding, pregnant or female with in-
adequate contraception, or were less than 18 years old.
Randomallocation toMS or MMFwas performed bymini-
mization using a computer algorithm. Minimization strata
were age (≥ versus <40 years), diagnosis (SLE versus PSV)
and baseline renal function (serum creatinine > versus
≤120 μmol/L [1.36 mg/dL]).
Patients in the MMF group were commenced on 2000
mg/day in two divided doses, and increased to 3000 mg/
day if disease control was inadequate and the drug was
tolerated. Patients in the MS group were commenced on
1440 mg/day in two divided doses, with increases to 2160
mg/day permitted for inadequate disease control. The MS
and MMF therapeutic regimens targeted equimolar MPA
doses and are considered bioequivalent in terms of MPA
area under the curve (AUC) in transplant patients [35].
Other immunosuppressive drugs were discontinued at
trial entry. Daily oral prednisolone was prescribed as
needed and reduced according to clinical improvement.
The primary outcome was a composite of treatment
failure and/or treatment intolerance by 12 months. Treat-
ment failure was defined as failure to achieve remission
by 6 months or disease relapse, in those achieving remis-
sion and remaining on therapy to 12 months. Treatment
intolerance was defined as an inability to tolerate and
maintain the target dose of (ECMS 1440 mg/day or MMF
2000 mg/day) within the 12 month study period. Patients
who died during the trial were recorded as treatment fail-
ures and those lost to follow-up were censored. This com-
posite end point was chosen to reflect the overall relative
clinical utility of the different MPA preparations. Secondary
end points were: treatment failure (failure to achieve re-
mission or relapse), treatment intolerance, time averaged
prednisolone dose, serious adverse events and serious in-
fection rates.
Evaluations were performed at entry and then three
monthly until trial completion at 12 months. At baseline,
patients were classified according to reason for commen-
cing MPA therapy; new disease, relapsing disease, refractory
disease or remission maintenance either after cyclophos-
phamide induction therapy or after withdrawal of a poorly
tolerated maintenance immunosuppressant. Refractory
disease was defined as disease unresponsive to all prior
immunosuppressive therapies [36]. At each assessment
disease activity was scored using British Isles Lupus Activ-
ity Grade (BILAG) [37] for SLE and Birmingham Vasculitis
Activity Score (BVAS) [38] for vasculitis. Glomerular filtra-
tion rates (GFR) were calculated using the four variable
MDRD equation. Adverse events were classified using the
EU Clinical Trials Directive (2001/20/EC), according to se-
verity (mild, moderate, severe, life-threatening or death),
seriousness (not serious, death, life-threatening, perman-
ently disabling, requiring hospitalization, prolongation of
hospitalization, cancer, or congenital anomaly) and rela-
tion to study medication (not related, unlikely, possibly,
probably or definitely related). Pre-dose MPA measure-
ments were obtained on up to three occasions per patient
after a stable dose of study drug had been established.
Samples were analysed for total MPA at trial end by high
performance liquid chromatography (HPLC).
For SLE complete remission required the absence of
BILAG grade A, B and C level disease activity and partial
remission required the absence of BILAG A and B activity.
For vasculitis complete remission was defined as BVAS ≤1
and partial remission required ≥50% reduction in BVAS
compared with entry. Relapse was defined as the appear-
ance of symptoms attributable to PSV or SLE necessitating
a change in immunosuppressive therapy or an increase in
corticosteroid dose by at least 10 mg/day [36].
Based on results of previous studies [8, 21–31] the fre-
quency of the primary composite outcome of treatment
failure or treatment intolerance was estimated at 70% in
the control (MMF) group (30% intolerance, and at least
20% remission failure and 20% relapse). With 20 patients
per limb this study was powered to detect an absolute risk
reduction of 35% in MS patients with a power of 0.8 and a
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two sided significance level of 0.05. All analyses were per-
formed according to the intention to treat principle. The
results are expressed as values and percentages for cat-
egorical variables and medians and ranges for continuous
variables. The primary outcome and secondary efficacy
and tolerability outcomes were assessed using unadjusted
Cox proportional hazards model. Continuous variables
were analysed by Wilcoxon signed rank test (paired data)
or Mann–Whitney test (unpaired data). Adverse events
were expressed as incidence rates. A value of P < 0.05 was
considered significant for all statistical tests.
Results
Forty patients (20 MMF and 20 MS) were enrolled between
November 2005 and September 2006. One MMF patient
was lost to follow-up shortly after trial entry, and two in
the MMF group died (Supplementary Figure S1). The base-
line characteristics of the patients are shown in Table 1. At
entry, active disease was present in 12/20 MS (2 new
disease, 9 relapsing, 1 refractory) and 13/20 MMF (3 new
disease, 7 relapsing, 3 refractory). The remainder received
therapy for remission maintenance either after cyclophos-
phamide induction, or after withdrawal of another
therapy due to intolerance (8/20 MS, 7/20 MMF). All pa-
tients were receiving immunosuppressive therapies prior
to entry, except those with new disease.
The groups were broadly similar except the MMF group
contained more patients with refractory disease, granulo-
matosis with polyangiitis (GPA, Wegener’s) and had worse
renal function (Table 1).
Primary outcomes
The primary outcome at 12 months, a composite end
point of treatment and/or tolerability failure, occurred in
11/20 (55%) MS and 17/20 (85%) MMF patients. Analysis
by Cox proportional hazard model found the primary
outcome to be significantly lower in the MS group (hazard
ratio 0.37; 95% CI 0.17–0.80; P = 0.012). Multivariable ana-
lysis found that the lowest tertile of GFR (≤40 mL/min/
1.73 m2) was strongly associated with the primary
outcome (P = 0.003). This association decreased over time
becoming neutral at 158 days. The dominant outcome
during the first 158 days was treatment intolerance rather
than treatment failure. Overall, treatment withdrawal due
to intolerance occurred in 6/13 (46%) patients with GFR
≤40 mL/min compared with 4/27 (15%) with GFR >40 mL/
min. Figure 1A and B illustrates time to primary outcome
with stratification according to entry GFR and Table 2 shows
a breakdown of the composite end point.
Secondary outcomes
Efficacy. Treatment failure by Month 12 occurred in 6/20
(30%) MS and 8/20 (40%) MMF patients (hazard ratio 0.28;
Table 1. Patient characteristics at entry to the trial
Demographics (median and range)
MS
N = 20
MMF
N = 20
Age (years) 58.5 (29–79) 57.5 (34–75)
Sex M:F 12:8 10:10
Patients previously treated with CYC 13/20 14/20
Prior cumulative CYC (grams) 9.9 g(5.67–163) 9 g(3–13.5)
Prior relapses 1 (0–3) 1 (0–3)
Disease duration (months) 22.4 (1–196) 26.5 (1–127)
MDRD GFR (mL/min) 83 (15–153) 71.5 (10–151)
ANCA positive at entry 6 6
Prior IS therapies 2 (0–6) 2 (0–5)
Dialysis at entry 0 2
Diagnoses (patient no.)
SLE 2 2
Vasculitis 18 18
AAV (GPA/MPA/CSA) 9 (5/2/2) 12 (9/2/1)
HSP 3 2
PAN 1 1
Other 4 3
Treatment prior to entry (patient no.)
CYC/AZA 13 (8/5) 12 (6/6)
IVIG 0 2
PEX 0 1
Dapsone 1 0
Prednisolone alone 4 2
Hydroxychloroquine 0 1
None 2 3
Disease state at entry (patient no.)
Active disease New 2 3
Refractory 1 3
Relapsing 9 7
Total 12 13
Remission
maintenance
Post CYC induction 4 2
Switch from other IS 4 5
Total 8 7
Fig. 1. (A) Primary composite end point; treatment and tolerability failure stratified for GFR > 40 mL/min. One MMF patient with GFR > 40 mL/min was lost
to follow-up and censored at 30 days, 9/12 patients reached the primary end point during follow-up and 2/12 patients were free from the primary end
point at 360 days. (B) Primary composite end point; treatment and tolerability failure stratified for GFR ≤40 mL/min. Treatment failure is defined as failure
to achieve remission with study drug or relapse with study drug. Tolerability failure is defined as withdrawal from study drug due to intolerance or inability
to maintain target dose (2000 mg/day MMF, 1440 mg/day MS). Time to failure to achieve and maintain target dose is time of dose reduction below target
dose.
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95% CI 0.095–0.82; P = 0.020). However, there was no sig-
nificant difference between groups with respect to pred-
nisolone use. Time averaged median prednisolone doses
were 9.1 mg/day (range 0–14.1 mg/day) for MMF patients
versus 7.6 mg/day (range, 0–18.6 mg/day) for MS patients
(P = 0.53).
Failure to achieve remission occurred in 2/20 (10%) MS
patients and 3/20 (15%) MMF patients treated for active
disease. Relapses were recorded for patients who achieved
remission or were in remission at trial start. Relapse by 12
months occurred in 4/18 (22%) MS patients and 5/17 (29%)
MMF patients (Table 2).
Intolerance. Target dose intolerance occurred in 7/20
(35%) MS patients (treatment withdrawal n = 5) versus 10/
20 (50%) MMF patients (treatment withdrawal n = 5). Ana-
lysis by Cox proportional hazard model found no signifi-
cant difference between treatment groups (Hazard ratio
0.53; 95% CI 0.20–1.42; P = 0.21). Treatment withdrawal
for intolerance was strongly associated with low GFR. In
MMF patients median GFR was 23.5 mL/min (range 0–131
mL/min) for those intolerant of target dose and 85.5 mL/
min (range 40–151 mL/min) for those tolerant of target
dose (P = 0.0015) (Supplementary Figure S2). Gastrointes-
tinal disturbance was the dominant reason for intolerance
in both groups (75% MS, 65% MMF).
Pre-dose MPA samples were obtained from 16 MS pa-
tients (n = 34) and 13 MMF patients (n = 33) at a median of
two occasions per patient. Samples were obtained from
patients receiving stable treatment doses; therefore no
samples were obtained from patients withdrawing from
treatment early due to intolerance. In those patients who
continued treatment long enough to achieve a stable
daily dosing pattern, median MPA levels were 1.45 mg/L
(range, 0.4–7.8 mg/L) MS versus 3.4 mg/L (range, 0.4–8.5
mg/L) MMF (P = 0.003). Drug-related toxicity at the time of
MPA sample occurred in 2/22 with MPA levels <1.5 mg/L
compared with 10/45 with levels >1.5 mg/L.
Adverse events. Severe adverse events were those that
resulted in alteration, discomfort or disability that was
damaging to the patient’s health and prevented normal
everyday activities, or those that resulted in a life-threa-
tening situation or death. Severe events occurred in 18/20
(90%) MS (n = 27), and 16/20 (80%) MMF patients (n = 35),
including two deaths in the MMF group. One 43-year-old
with SLE, cardiac disease and end-stage renal failure suf-
fered a sudden cardiac death at 8 months, having had
MMF withdrawn at 5 months. One 72 year old with micro-
scopic polyangiitis, end-stage renal failure and peripheral
vascular disease died as a result of septic and cardiogenic
shock following surgery for a gangrenous leg at 11months.
At the time of hospitalization this patient was still receiv-
ing MMF (Table 3).
Moderate or severe infections occurred in 10/20 (50%)
MS patients (n = 19) and 7/20 (35%) MMF patients (n = 11)
(Table 3).
Serious adverse events occurred in 11/20 (55%) MS
patients and 9/20 (45%) MMF patients. Thirteen events
occurred in MS (incidence rate 1.29 per patient year), and
23 events occurred in MMF patients (incidence rate 3.03
per patient year) meaning that a difference of 1.74 events
per patient year occurred between MS and MMF groups
(95% CI 0.26–3.2; P = 0.015). No serious events were dir-
ectly attributed to the study medications. In MS patients
serious events were 5 infections (0.5 per patient year), 1
active disease whilst taking MS, 7 relating to medical
comorbidities. In MMF patients serious events were 2
Table 2. Breakdown of composite primary end point
6 months 12 months
MS MMF MS MMF
Primary composite end point 7 15 11 17
Treatment failure 2(2) 5(6) 5(6) 7(8)
Remission failure 1(1) 1(2) 1(2) 2(3)
Relapsea 1(1) 4(4) 4(4) 5(5)
Treatment intolerance 5(6) 10(10) 6(7) 10(10)
Treatment withdrawal due
to intolerance
5(5) 5(5) 5(5) 5(5)
aRelapses are reported for patients in remission at entry and for patients
who achieved remission with the study drug; not for patients who failed to
achieve remission with the study drug. First event for each patient is
recorded for the primary composite end point. Numbers in brackets
indicate total number of patients suffering each event. Follow-up was
censored after the first event for composite primary end point, intention to
treat analysis. Numbers in brackets indicate total number of patients
suffering each event.
Table 3. Adverse events
Any event
Total number (%patients)
MS
(N = 20)
MMF
(N = 20)
Severity grade 1/2 116 (100%) 36 (80%)
Severity grade 3/4/5 27 (90%) 35 (80%)
Serious events
Hospitalization/life-threatening 13 (55%) 23 (45%)
Cancer 0 0
Death 0 2 (10%)
Drug-related events occurring in ≥10%
patients in either group
Gastrointestinal 15(75%) 13 (65%)
Anaemia 3 (15%) 3 (15%)
Lowmood 5 (25%) 4 (20%)
Rash 4 (20%) 0
Leucopenia 2 (10%) 1 (5%)
Insomnia 0 4 (20%)
Tremor 2 (10%) 2 (10%)
Infections
All infection 38 (75%) 15 (50%)
Serious infectionsa 5 (20%) 2 (10%)
Moderateb/severec infections ≥10%
patients in either group
Chest 3 (10%) 4 (20%)
Gastroenteritis 4 (20%) 2 (10%)
Upper respiratory tract 4 (15%) 0
Skin 4 (15%) 2 (10%)
Herpes Zoster 2 (10%) 1 (5%)
Adverse events were graded according to severity (Grades 1–5) and
seriousness.
Grade 1 = Mild: The adverse event does not interfere with the subject’s
daily routine. It causes slight discomfort. Grade 2 = Moderate: The adverse
event interferes with some aspects of the subject’s daily routine, not
damaging health. Grade 3 = Severe: The adverse event results in alteration,
discomfort or disability that is damaging to the patient’s health and
prevents normal every day activities. Grade 4 = Life-threatening. Grade
5 = Death. Serious adverse events were those that resulted in
hospitalization, prolongation of hospitalization, permanent disability,
a life-threatening situation, cancer or death.
aSerious infections were those that resulted in hospitalization,
prolongation of hospitalization, permanent disability, a life-threatening
situation, or death.
bModerate infections were those that interfered with some aspects of the
patient’s daily routine, not damaging health.
cSevere infections were those that resulted in alteration, discomfort or
disability that is damaging to the patient’s health and prevents normal
everyday activities, or were life-threatening or caused death.
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infections (0.29 per patient year), 13 active disease (7
whilst taking MMF, 6 after MMF withdrawal), 8 relating to
medical comorbidities. The observed difference in serious
infection rates of 0.21 between groups was non-signifi-
cant (95% CI 0.38–0.80; P = 0.55).
Events related to the study medications were similar
between groups. Most frequent were gastrointestinal side
effects in 15/20 (75%) MS and 13/20 (65%) MMF patients.
These were moderate or severe in 8/20 (40%) MS and 10/
20 (50%) MMF patients and resulted in drug withdrawal in
5/20 (25%) of both MS and MMF groups. A further 2/20
(10%) MS and 5/20 (25%) MMF patients failed to achieve
and maintain study drug target dose.
Discussion
In this randomized trial of MS versus MMF in vasculitis and
SLE, MS was associated with a significantly lower rate of
the composite primary end point of treatment failure and/
or treatment intolerance. Intolerance rates alone did not
differ between groups; however, MS was associated with a
significant reduction in treatment failure alone. Differ-
ences in baseline characteristics between groups may
account for some of the observed effect of MS in our trial,
with more MMF patients having GPA (Wegener’s) and/or
refractory disease. Overall intolerance rates were higher
than previous studies. However, unlike previous studies,
we included patients with renal failure. Kidney disease
with an estimated GFR ≤40 mL/min was common (35%
patients) and was strongly associated with intolerance
leading to treatment withdrawal.
Treatment intolerance rates between MS and MMF may
differ. The absorption characteristics of MS and MMF influ-
ence MPA pharmacokinetic profiles. Equimolar MS and
MMF are associated with equivalent total MPA area under
the curve concentrations and IMPDH blockade; however,
MS has been associated with a longer time to maximum
plasma concentration [33]. In transplantation, cross-over
studies have found a reduction in gastrointestinal intoler-
ance after switching from MMF to MS [13–17], although
blinded randomized trials have not demonstrated a differ-
ence in tolerability [19, 20]. In autoimmunity, higher doses
of MMF (2000–3000 mg/day) and pre-dose target MMFMPA
levels (3.5–4.5 mg/L) [39] are used compared with trans-
plantation (1000–2000 mg/day MMF, 1.0–3.5 mg/L trough
MMF MPA range with ciclosporin) [40]. Correspondingly
MMF intolerance rates are higher in autoimmunity. Theor-
etically pharmacokinetic differences between MS and MMF
may have a greater impact on intolerance and loss of
efficacy in autoimmunity compared with transplantation.
However, in our trial comparing MS and MMF in auto-
immune disease, no significant difference in treatment in-
tolerance was identified.
Overall, our intolerance rates were high compared with
previous MMF trials in autoimmunity, with 70% of the pa-
tients suffering gastrointestinal side effects and 45%
being unable to tolerate the target dose. In lupus nephritis
gastrointestinal intolerance rates of 30% have been re-
ported with similar MMF doses [41]. In this trial intolerance
correlated strongly with a GFR ≤40 mL/min, which was
present in 35% at baseline. The majority of previous ran-
domized SLE and vasculitis trials have excluded patients
with severe renal impairment. Our results are consistent
with a previous report of MMF intolerance in five AAV pa-
tients with end-stage renal failure [42], none of whom
could tolerate 2000 mg/day. In renal failure, accumulation
of the MPA metabolites, inactive MPA-glucuronide (MPAG)
and active toxic acyl MPA-glucuronide (AcMPAG) occurs.
Increased MMF intolerance in advanced renal failure may
be a direct toxic effect of AcMPAG or indirectly by an in-
crease in free MPA, due to altered protein binding and the
displacement of MPA from protein by MPAG [35, 43, 44]. Ef-
ficacy was not affected by low GFR in those patients who
continued treatment albeit at sub-target dose. Our results
confirm that cautious dosing of MS and MMF is required in
renal failure. This study has not addressed whether lower
doses are sufficient for disease control in renal failure;
however, the increase in free MPA and MPA metabolites in
renal failure would support this hypothesis.
Combined remission failure and relapse rates were
significantly lower in MS patients compared with MMF
patients. It is unclear whether this is a true effect of treat-
ment or due to imbalances between groups. More MMF
patients had GPA (Wegener’s), which is associated with
high relapse rates, and more MMF patients had refractory
disease, which is associated with remission failure. Overall,
our remission failure and relapse rates were higher com-
pared with previous trials of MMF in AAV [26] and lupus
nephritis [21–23]. Unlike previous trials, the majority of
our patients had relapsing or refractory diseases and a
few had non AAV diagnoses whose optimal treatment re-
sponses are less well established. Our efficacy rates are
consistent with those observed in retrospective studies of
MMF in PSV [31], as well as those achieved in uncontrolled
refractory vasculitis trials of intravenous immunoglobulin
[45], alemtuzumab [46] and gusperimus [47]. Notably the
B-cell-depleting anti-CD20 therapy, rituximab licensed
for remission induction in AAV, has been associated with
remission rates of 80% in similar patient groups and,
although relapses subsequently occur, further rituximab
courses are effective in the majority [48].
During this trial, pre-dose MPA levels were obtained
from patients achieving stable maintenance doses of
study drug. We observed a trend towards higher treatment
intolerance with MPA levels above 1.5 mg/L. Because 25%
of patients from both groups withdrew from treatment
early due to intolerance, samples were obtained from a
subgroup of patients only. Interpretation of tolerability
correlations was therefore limited. MMF and MS produce
equivalent steady state MPA exposure (AUC) [35]; MS
trough levels have been more variable and generally
higher than MMF trough levels due to the delayed absorp-
tion characteristics of MS [35, 49, 50]. Our MPA levels
in MMF patients were comparable to levels previously
observed in autoimmunity [39] whereas MS levels were
significantly lower than MMF levels despite adjustment for
dose and GFR. We confirm the low predictability of MS
trough levels in an autoimmune clinical setting.
Serious adverse event rates were higher in MMF patients
compared with MS patients as a result of differences in
hospitalizations due to active disease (MS 1 event, MMF 13
events in 7 patients). This high rate in MMF patients may
largely be attributable to group imbalances with more
MMF patients having refractory disease or GPA (Wegener’s)
with increased susceptibility to relapse or remission
failure. Serious infection rates did not differ between
groups and were comparable with other cohorts with
longstanding disease treated with MMF [31] or therapies
such as gusperimus [47] and rituximab [48]. Lower serious
infection rates have been observed in trials of MMF in pa-
tients with new disease in whom prior disease damage
and immunosuppression exposure is low.
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Conclusion
In this trial of MS versus MMF in multi-system autoimmune
disease, MS was associated with a significantly lower rate
of the composite primary outcome: treatment failure and/
or tolerability failure. No difference in treatment intoler-
ance was detected; however, MS was associated with a
lower treatment failure rate. Given the limitations of our
study, small sample size and differences in baseline char-
acteristics that potentially affect efficacy outcomes, larger
studies are warranted to further investigate any efficacy
differences between MS and MMF in patients with multi-
system autoimmune disease. This trial identified that GFR
was strongly associated with treatment intolerance. Future
studies should include detailed assessment of MPA pharma-
cokinetics in different stages of chronic kidney disease.
Supplementary data
Supplementary data is available online at http://ndt.
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